Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
9Customers
3Debt Items
8Related Chains
Source-Backed Evidence Depth
Ernexa Therapeutics Inc. (ERNA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
2Distinct source URLs
9High confidence
0.796Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Ernexa Therapeutics Inc. Suppliers
Ticker
Name
Confidence
Evidence
LESSOR-OF-THE-MANHATTAN-OFFICE
LESSOR-OF-THE-MANHATTAN-OFFICE
90%
The Company agreed to surrender and vacate the premises in exchange for a termination payment of approximately $ 72,000 to the lessor.
Ernexa Therapeutics Inc. Customers
Ticker
Name
Confidence
Evidence
FACTOR-BIOSCIENCE
FACTOR-BIOSCIENCE
92%
The Assignment Agreement with Factor Bioscience assigned all our rights and obligations under the customer contract to Factor Bioscience
FACTOR-LIMITED
FACTOR-LIMITED
92%
In September 2024, we entered into an agreement with Factor Limited (and together with Factor Bioscience Inc. and its other affiliates, “Factor Bioscience”) whereby we assigned the customer contract …
FACTOR-BIOSCIENCE-INC
FACTOR-BIOSCIENCE-INC
85%
illion towards the customization fee, which we were recognizing ratably over the customization period for the year ended December 31, 2024. The Company did not recognize any revenue during the year e…
Reciprocal relationship from FBIO graph: Reciprocal relationship from ERNA graph: illion towards the customization fee, which we were recognizing ratably over the customization period for the year en…
ARCADIA-SECURITIES-LLC
ARCADIA-SECURITIES-LLC
62%
condensed consolidated statement of operations for the three months ended March 31, 2026. On February 18, 2026, the Company entered into a lease termination agreement with the lessor of the Manhattan…
FACTOR-BIOSCIENCE-LIMITED
FACTOR-BIOSCIENCE-LIMITED
62%
iginal issuance date or (ii) the 180 th calendar day following our public release of clinical trial data from the first cohort of the Phase 1 study of ERNA-101. Pursuant to the Placement Agency Agree…
FACTOR-L-C-AGREEMENT-FACTOR-LIMITED
FACTOR-L-C-AGREEMENT-FACTOR-LIMITED
62%
with our limited financial resources and substantial capital requirements, make it difficult to assess our prospects. We have incurred significant net losses since inception. As of December 31, 2025,…
LINCOLN-PARK-CAPITAL-FUND-LLC
LINCOLN-PARK-CAPITAL-FUND-LLC
62%
in the fair value of the liability. There were no amounts recognized for the year ended December 31, 2025. The contingent consideration liability will expire in April 2026. Interest Income We recogni…
ROCHE-GROUP
ROCHE-GROUP
62%
ns may be subject to procedural or legal challenges by others. We may be unable to obtain, maintain and protect the intellectual property rights necessary to conduct our business, and we may be subje…
Ernexa Therapeutics Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ERNA-DEBT-9351
Warrants outstanding: 6100000
90%
xbrl warrant detail from xbrl 2025-12-31.
ERNA-DEBT-9352
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
ERNA-DEBT
Debt stack $389,000
90%
Market cache reports total debt of $389,000.
Ernexa Therapeutics Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Ernexa Therapeutics Inc..
Ernexa Therapeutics Inc. Ownership
Holder
Name
Confidence
Evidence
ERNA-OWNER-CORIENT-PRIVATE-WEALTH-LLC
Corient Private Wealth LLC
90%
13F overlay lists Corient Private Wealth LLC as top holder; 10 tracked holders.
Ernexa Therapeutics Inc. Extended Supply Chain Network
